Billy, I understand the H1 impairment, but that was my point. So far we have :
1) $151m impairment for Hamilton (H1)
2) $115m impairment for US Rehab (H2)
3) Unspecified but "likely" impairment for Metalysis investment as per Q3 report (H2)
That's close to $300m in impairments this year. If the broker consensus is for NPAT of ~$120 million, the underlying profit before impairments would have to be in the order of $400m which I just don't see.
Like you I'm also interested in the cash situation, but the media are more likely to report the headline NPAT number. We'll find out tomorrow !
Billy, I understand the H1 impairment, but that was my point. So...
Add ILU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.31 |
Change
-0.060(0.81%) |
Mkt cap ! $3.128B | |||
| Open | High | Low | Value | Volume |
| $7.32 | $7.37 | $7.26 | $4.904M | 670.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12864 | $7.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.35 | 260 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$7.32 |
Change
-0.060 ( 1.05 %) |
||||
| Open | High | Low | Volume | ||
| $7.32 | $7.37 | $7.26 | 103669 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| ILU (ASX) Chart |